US 12,285,400 B2
Sulfopropanoic acid derivatives for treating neurodegenerative disorders
Petr Kocis, Framingham, MA (US); John Hey, Framingham, MA (US); and Martin Tolar, Framingham, MA (US)
Assigned to Alzheon, Inc., Framingham, MA (US)
Appl. No. 17/264,478
Filed by Alzheon, Inc., Framingham, MA (US)
PCT Filed Jul. 30, 2019, PCT No. PCT/US2019/044114
§ 371(c)(1), (2) Date Jan. 29, 2021,
PCT Pub. No. WO2020/028348, PCT Pub. Date Feb. 6, 2020.
Claims priority of provisional application 62/713,056, filed on Aug. 1, 2018.
Prior Publication US 2022/0087967 A1, Mar. 24, 2022
Int. Cl. A61K 31/221 (2006.01); A61K 31/185 (2006.01); A61K 31/22 (2006.01); A61P 25/28 (2006.01)
CPC A61K 31/221 (2013.01) [A61K 31/185 (2013.01); A61K 31/22 (2013.01); A61P 25/28 (2018.01)] 16 Claims
OG exemplary drawing
 
1. A method of treating a subject suffering from Alzheimer's disease, comprising the step of administering to the subject an effective amount of a compound of Formula I:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
R1 is selected from —O—R3,—O—R4—CH (NHR6)—C(O)—R5, and —[N(R6)—CH(R7)—C(O)]1-2—R5;
R2 is selected from hydrogen, R3, and R4—CH(NHR6)—C(O)—O—R5;
each R3 is independently selected from C1-C20 alkyl,-C2-C20 alkenyl,-C2-C20 alkynyl, -(C0-C20 alkylene)-aryl,-(C0-C20 alkylene)-carbocyclyl,-(C0-C20 alkylene)-heterocyclyl,-(C0-C20 alkylene)-heteroaryl,-(C2-C20 alkenylene)-aryl,-(C2-C20 alkenylene)-carbocyclyl,-(C2-C20 alkenylene)-heterocyclyl,-(C2-C20 alkenylene)-heteroaryl,-(C2-C20 alkynylene)-aryl,-(C2-C20 alkynylene)-carbocyclyl,-(C2-C20 alkynylene)-heterocyclyl, and-(C2-C20 alkynylene)-heteroaryl;
each R4 is an independently selected from -CH(CH3)-,-CH2-,

OG Complex Work Unit Chemistry
each R5 is independently selected from —OH,—O—C1-C4 alkyl and —NH2;
each R6 is independently selected from hydrogen and —C(O)R8;
R7 is a side chain of an α-amino acid; and
each R8 is independently selected from hydrogen, C1-C4 alkyl,—O—C1-C4 alkyl,—(C1-C4 alkylene)-aryl, and (C1-C4 alkoxy)-aryl;
wherein:
each alkyl, alkylene, alkenyl, alkenylene, alkynyl or alkynylene portion of R3 is optionally substituted with up to 6 substituents independently selected from halo,—OH,—O—(C1-C4 alkyl),—O—(C1-C4 haloalkyl), carbocyclyl, aryl, heterocyclyl, and heteroaryl;
each carbocyclyl, aryl, heterocyclyl, or heteroaryl portion of R3 is optionally substituted with up to four substituents independently selected from halo,—OH,—O—(C1-C4 alkyl),—O—(C1-C4 haloalkyl), C1-C18 alkyl, C2-C18 alkenyl, and C2-C18 alkynyl, wherein the alkyl, alkenyl, or alkynyl portions of the C1-C18 alkyl, C2-C18 alkenyl, or C2-C18 alkynyl, respectively, are optionally substituted with up to six substituents independently selected from halo,-OH,-O-(C1-C4 alkyl), and-O-(C1-C4 haloalkyl);
R1 comprises no more than 2 cyclic moieties; and
R2 comprises no more than 2 cyclic moieties.